Evaluation of Anti-Xa and Activated Partial Thromboplastin Time Monitoring of Heparin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Support
Authors:
- 1 March 2020
- journal article
- research article
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 66 (3) , 300-306
Abstract
The approach to monitoring anticoagulation in adult patients receiving heparin on extracorporeal membrane oxygenation (ECMO) support is controversial. The objective of this study was to compare the correlation between anti-Xa and activated partial thromboplastin time (aPTT) with heparin dose and to describe their association with clinical events in adult ECMO patients. We conducted a retrospective single-center study of 34 adult ECMO patients whose heparin was monitored by anti-Xa and/or aPTT. The heparin dose-to-assay correlation coefficient was 0.106 for aPTT and 0.414 for anti-Xa (p < 0.001). Major thrombotic and hemorrhagic events occurred in 14.7% and 26.5% of patients, respectively. The median anti-Xa in patients who experienced a major thrombotic event was 0.09 (0.06–0.25) IU/mL compared with 0.36 (0.26–0.44) IU/mL in patients who did not (p = 0.031), whereas the median aPTT did not differ between these groups. The maximum aPTT in patients who experienced a major bleed was 96.9 (76.0–200) seconds compared with 63.5 (44.4–98.6) seconds in patients who did not (p = 0.049), whereas the maximum anti-Xa did not differ between these groups. Monitoring both anti-Xa and aPTT may be warranted to safely provide understanding of pure heparin activity as well as underlying bleeding diatheses in adult ECMO patients.Keywords
This publication has 24 references indexed in Scilit:
- Evaluation of heparin dosing based on adjusted body weight in obese patientsAmerican Journal of Health-System Pharmacy, 2016
- Anti-Xa Directed Protocol for Anticoagulation Management in Children Supported With Extracorporeal Membrane OxygenationASAIO Journal, 2015
- Unfractionated Heparin Activity Measured by Anti-Factor Xa Levels Is Associated With the Need for Extracorporeal Membrane Oxygenation Circuit/Membrane Oxygenator ChangePediatric Critical Care Medicine, 2014
- Anti-Factor Xa Assay Is a Superior Correlate of Heparin Dose Than Activated Partial Thromboplastin Time or Activated Clotting Time in Pediatric Extracorporeal Membrane Oxygenation*Pediatric Critical Care Medicine, 2014
- Technological advances in extracorporeal membrane oxygenation for respiratory failureExpert Review of Respiratory Medicine, 2012
- Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated HeparinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Parenteral AnticoagulantsChest, 2012
- Evaluation of Heparin Assay for Coagulation Management in Newborns Undergoing ECMOAmerican Journal of Clinical Pathology, 2010
- Anticoagulation and Coagulation Management for ECMOSeminars in Cardiothoracic and Vascular Anesthesia, 2009
- Challenges in Variation and Responsiveness of Unfractionated HeparinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004